Karuna Therapeutics (Karuna Therapeutics) Debt-to-Equity : 0.01 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Karuna Therapeutics Debt-to-Equity?

Karuna Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.84 Mil. Karuna Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13.85 Mil. Karuna Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,254.24 Mil. Karuna Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Karuna Therapeutics's Debt-to-Equity or its related term are showing as below:

KRTX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.87 Med: 0.01 Max: 0.02
Current: 0.01

During the past 7 years, the highest Debt-to-Equity Ratio of Karuna Therapeutics was 0.02. The lowest was -0.87. And the median was 0.01.

KRTX's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15 vs KRTX: 0.01

Karuna Therapeutics Debt-to-Equity Historical Data

The historical data trend for Karuna Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karuna Therapeutics Debt-to-Equity Chart

Karuna Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.02

0.01

Karuna Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.01	-	0.01	0.01	0.01

Competitive Comparison of Karuna Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Karuna Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karuna Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karuna Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Karuna Therapeutics's Debt-to-Equity falls into.

Karuna Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Karuna Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.843	+	13.845)	/	1254.235
	=	0.01

Karuna Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.843	+	13.845)	/	1254.235
	=	0.01

Karuna Therapeutics (NAS:KRTX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Karuna Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Karuna Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Karuna Therapeutics (Karuna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karuna Therapeutics Inc (NAS:KRTX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

KRTX:Mexico

Address

99 High Street, 26th Floor, Boston, MA, USA, 02110

Website

https://www.karunatx.com

Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.

Executives

Stephen K. Brannan	officer: Chief Medical Officer	C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Jason Parker Brown	officer: Chief Financial Officer	KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Jeffrey M Jonas	director	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Troy A. Ignelzi	officer: Chief Financial Officer	C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Andrew Craig Miller	officer: Chief Operating Officer	C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Laurie J Olson	director	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Kane William P Jr	officer: Chief Commercial Officer	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
William Meury	director, officer: President and CEO	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Charmaine Lykins	officer: Chief Commercial Officer	C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Steven M Paul	director, officer: President & CEO	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Puretech Health Llc	10 percent owner	501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045